Clebopride

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Clebopride is a dopamine antagonist used to treat symptoms associated with functional gastrointestinal disorders. Clebopride may also be used to treat nausea and vomiting associated with chemotherapy.

Generic Name
Clebopride
DrugBank Accession Number
DB13511
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 373.88
Monoisotopic: 373.1557047
Chemical Formula
C20H24ClN3O2
Synonyms
  • Cleboprida
  • Clebopride
External IDs
  • LAS 9273

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Symptomatic treatment ofFunctional dyspepsia••••••••••••
Treatment ofGastrointestinal disorder••••••••••••••••••
Symptomatic treatment ofNausea and vomiting••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Clebopride.
AripiprazoleThe therapeutic efficacy of Aripiprazole can be decreased when used in combination with Clebopride.
BenzatropineThe risk or severity of adverse effects can be increased when Clebopride is combined with Benzatropine.
BrexpiprazoleThe therapeutic efficacy of Brexpiprazole can be decreased when used in combination with Clebopride.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Clebopride.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
A03FA06 — Clebopride
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Aminophenyl ethers / Methoxyanilines / Phenylmethylamines / Phenoxy compounds / Anisoles / Methoxybenzenes / Benzylamines / Alkyl aryl ethers / Aralkylamines / Chlorobenzenes
show 9 more
Substituents
Alkyl aryl ether / Amine / Aminophenyl ether / Aniline or substituted anilines / Anisole / Aralkylamine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
I0A84520Y9
CAS number
55905-53-8
InChI Key
BVPWJMCABCPUQY-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)
IUPAC Name
4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide
SMILES
COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC2=CC=CC=C2)CC1

References

General References
  1. SehatQ: Clast (clebopride maleate) oral tablets [Link]
  2. AIFA Product Information: Motilex (clebopride maleate) for oral or parenteral administration [Link]
  3. National Center for Advancing Translational Sciences: Clebopride [Link]
ChemSpider
2678
BindingDB
50132693
RxNav
21224
ChEBI
92309
ChEMBL
CHEMBL325109
ZINC
ZINC000000608261
Wikipedia
Clebopride

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral
TabletOral
CapsuleOral
EmulsionOral
SolutionOral6.250 mg
TabletOral500 mcg
Injection, solutionIntramuscular; Intravenous1 MG/2ML
SyrupOral0.5 MG/5ML
TabletOral0.5 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0198 mg/mLALOGPS
logP2.69ALOGPS
logP2.42Chemaxon
logS-4.3ALOGPS
pKa (Strongest Acidic)14.61Chemaxon
pKa (Strongest Basic)8.52Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area67.59 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity106.07 m3·mol-1Chemaxon
Polarizability39.81 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0009000000-ab5c55bf9fc62a54ae2a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0209000000-0d6866e219bc706e9035
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uk9-0409000000-c6365e56f2a78b27944f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9522000000-48cac518944f434515ff
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dr-2419000000-92834ba2531376c09cf0
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-7495000000-13687544847a88f8cdc1
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.00618
predicted
DeepCCS 1.0 (2019)
[M+H]+188.56299
predicted
DeepCCS 1.0 (2019)
[M+Na]+196.18745
predicted
DeepCCS 1.0 (2019)

Drug created at June 23, 2017 20:43 / Updated at May 15, 2021 22:41